ADMA Biologics (ADMA) Tops Q4 EPS by 31c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. TENB
6. EBAY
7. CMG
8. KLAC
9. GOOG
10. BIIB

Go back to ADMA Biologics (ADMA) Tops Q4 EPS by 31c, Offers Guidance

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 3, 2025 4:05 PM EST

FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase

FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit

FY 2024 Adjusted EBITDA(1) of $164.6 Million, a 309% YoY Increase

FY 2024 Adjusted Net Income(2) of $119.2 Million, Compared to $0.7 Million in FY 2023, a 16,810% YoY Increase

YE 2024 Total Cash Grew to More than $103 Million, Including $60 Million of Debt Organically Discharged During 2H 2024

High-Titer Plasma Supply Contracts Expected to Provide Foundation... More